ILK (integrin-linked kinase) by Serrano, Isabel et al.
Gene Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(5) 324 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
ILK (integrin-linked kinase) 
Isabel Serrano, Paul McDonald, Shoukat Dedhar 
Department of Integrative Oncology, British Columbia Cancer Research Centre of the BC Cancer 
Agency, 675 West 10th Avenue, Vancouver, BC, Canada, V5Z1L3 (IS, PM, SD) 
Published in Atlas Database: August 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/ILKID460ch11p15.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62119/08-2014-ILKID460ch11p15.pdf 
DOI: 10.4267/2042/62119 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on ILK, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: HEL-S-28, ILK-1, ILK-2, P59, 
p59ILK 
HGNC (Hugo): ILK 
Location: 11p15.4 
DNA/RNA 
Description 
According to Entrez-Gene, human ILK maps to 
locus NC_000011.9. ILK gene contains 13 exons 
and spans 9.0 kb. 
Transcription 
ILK encodes a predicted 451-amino acid protein 
with an apparent molecular mass of 59 kD based on 
SDS-PAGE.  
Chromosome 11, genomic organization of human ILK. The ILK gene is located on chromosome 11 at position 15. Exactly 
from 6624961 bp to 6632102 bp (7142 bases) (Diagram author: Elena Serrano). 
Functional domains of integrin-linked kinase (ILK). ILK is an intracellular serine/threonine protein kinase with a C-terminal 
kinase catalytic domain. ILK structure consists in four ankyrin repeats at the N-terminus (residues 33-164), a phosphoinositide-
binding motif and a catalytic domain (residues 180-212). The integrin-binding site is in the extreme C-terminus of the kinase 
domain (residues 293-451) (Diagram author: Elena Serrano). 
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Northern blot analysis showed that the 1.8-kb ILK 
mRNA is widely expressed. 
Pseudogene 
An ILK pseudogene has been found in mice, 
predicted gene 6263 (Gm6263). 
Protein 
Description 
ILK is a widely expressed modular protein 
composed of three major domains: an N-terminal 
domain that contains four ankyrin repeats, a central 
pleckstrin homology (PH)-like domain and a C-
terminal kinase domain. The N-terminal ankyrin 
domain binds to PINCH (particularly interesting 
new cysteinehistidine protein) - an adaptor protein 
that complexes with ILK in the cytoplasm prior to 
active recruitment of ILK to focal adhesion sites - 
and to ILK-associated protein (ILKAP) - a protein 
phosphatase 2C (PP2C)-family protein phosphatase 
that negatively regulates ILK signaling (McDonald 
et al., 2008a). Adjacent to the ankyrin repeats, a 
sequence motif present in PH domains binds to the 
second messenger PI(3,4,5)P3 and a PI3-kinase-
dependent kinase activation has been reported 
(Delcommenne et al., 1998; Boulter and Van 
Obberghen-Schilling, 2006). The C-terminus kinase 
domain also interacts with integrins, as well as with 
the focal adhesion proteins paxillin (Nikolopoulos 
and Turner, 2001; Nikolopoulos and Turner, 2002) 
and parvins (Hannigan et al., 2005; Legate et al., 
2006), which link ILK, and therefore integrins, to 
the actin cytoskeleton. 
Expression 
ILK is ubiquitously expressed in most tissues, with 
predominance at skeletal muscle, heart, kidney and 
pancreas. Increased expression of ILK is correlated 
with progression of several tumor types, 
constituting an attractive therapeutic target in 
human cancer. 
Localisation 
ILK is generally considered a cytosolic protein 
localized at focal adhesions, however ILK co-
localizes with tubulins and many centrosomal and 
mitotic spindle associated proteins at centrosomes. 
Function 
Integrin-linked kinase (ILK) (Hannigan et al., 1996) 
is a multifunctional protein kinase which is 
implicated in a large number of cellular processes 
and diseases, participating in signal transduction 
pathways that control cell survival, differentiation, 
proliferation and gene expression in mammalian 
cells (Wu, 2001). ILK, PINCH1 and α-parvin form 
a ternary complex termed IPP (ILK-PINCH-parvin) 
that localizes to both focal adhesions (FAs) and 
fibrillar adhesions (FBs) and is essential for several 
integrin-dependent functions. The IPP complex, 
interacts with the cytoplasmic tail of β integrins, 
resulting in the engagement and organization of the 
cytoskeleton as well as activation of signalling 
pathways. Deletion of the genes encoding ILK or 
PINCH1 similarly blocks maturation of FAs and 
FBs by downregulating expression or recruitment 
of tensin and destabilizing α5β1-integrin-
cytoskeleton linkages (Legate et al., 2006; Stanchi 
et al., 2009; Elad et al., 2013). The kinase activity 
of ILK is stimulated by integrins and soluble 
mediators, including growth factors and 
chemokines, and is regulated in a phosphoinositide 
3-kinase (PI3K)-dependent manner. The activity of 
ILK is antagonized by phosphatases such as ILKAP 
and phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) (McDonald et al., 2008a). 
Important downstream targets of ILK signaling 
include PKB/Akt, GSK-3, β-catenin, p44/p42 MAP 
kinases, the myosin light chain (MLC) (Hannigan et 
al., 2011) and the Hippo pathway through Merlin's 
phosphatase MYPT1 (Serrano et al., 2013c). AKT 
is a regulator of cell survival and apoptosis. To 
become fully activated, PKB/Akt requires 
phosphorylation at two sites, threonine 308 and 
serine 473. Phosphorylation at serine 473 depends 
on PI3K activity (Persad et al., 2001), the rictor-
mTOR complex (Sarbassov et al., 2005) and the 
ILK-Rictor complex (McDonald et al., 2008b). 
GSK-3 is phosphorylated and inactivated at serine 9 
by ILK, regulating the cell cycle through 
proteolysis of cyclin D1 and activation of the 
transcription factor AP1 (Troussard et al., 1999). 
Inactivation of GSK-3 stabilizes β-catenin, whose 
accumulation is related to deregulation of 
proliferation, migration and differentiation (Oloumi 
et al., 2004). ILK can directly phosphorylate MLC 
on Ser18/thr19 influencing in cell contraction, 
motility and migration (Deng et al., 2001). ILK 
function is required in TGFβ-1-induced EMT in 
mammary epithelial cells, and the ILK/Rictor 
complex has been identified as a potential 
molecular target for preventing/reversing EMT 
(Serrano et al., 2013b). But ILK can also directly 
regulate EMT by promoting the expression of Snail 
transcriptionally (McPhee et al., 2008) and via 
posttranslational modification through GSK-3b. 
ILK also localize to centrosomes, where it is 
recruited by RUVBI1/2, and it regulates mitotic 
spindle assembly by promoting Aurora A 
kinase/TACC3/ch-TOG interactions (Fielding et al., 
2008) as well as centrosome clustering through the 
microtubule regulating proteins TACC3 and ch-
TOG (Fielding et al., 2011). In addition, ILK 
regulates microtubule dynamics since 
overexpression of ILK in HeLa cells is associated 
with a shorter duration of mitosis and decreased 
sensitivity to paclitaxel, a chemotherapeutic agent 
that suppresses microtubule dynamics and  
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ILK interaction partners. Schematic representation of the signal transduction pathways where ILK is implicated. Dark green 
represents direct interaction, red represents indirect interaction and light brown represents not analysed. Adapted from Widmaier 
et al., 2012 by Elena Serrano. 
 
conversely, the use of a small molecule inhibitor 
selective against ILK, QLT-0267, results in 
suppressed microtubule dynamics (Lim et al., 
2013). ILK regulation of microtubules is critical for 
proper trafficking of caveolin-1-containing vesicles. 
ILK controls this process by regulating microtubule 
stability through the recruitment of the scaffold 
protein IQGAP1 and its downstream effector 
mDia1 to nascent, cortical adhesion sites. In the 
absence of ILK, caveolae remain associated with 
dynamic microtubules, fail to stably fuse with the 
plasma membrane, and subsequently accumulate in 
intracellular structures (Wickström et al., 2010). 
Homology 
The ILK gene is highly conserved in a total of 24 
species. The most representatives are human, 
mouse, chicken, lizard, African clawed frog, 
zebrafish, fruit fly, worm. 
Mutations 
1. ILK mutation causes human cardiomyopathy via 
simultaneous defects in cardiomyocytes and 
endothelial cells (Knoll et al., 2007). 
2. Embryonic lethality was observed in Xenopus 
laevis (Yasunaga et al., 2005) and mouse (Sakai et 
al., 2003) models of ILK ablation, and this was 
attributed to defects in adhesive and migratory 
mechanics. 
Implicated in 
Melanoma 
Increased expression of integrin-linked kinase is 
correlated with melanoma progression and poor 
patient survival (Dai et al., 2003; Wong et al., 
2007). ILK regulates melanoma angiogenesis by 
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activating NF-kB/interleukin-6 signaling pathway 
(Wani et al., 2011). 
Colon cancer 
ILK is hyperexpressed in malignant crypts from 
both the primary and metastatic lesions. Changes in 
ILK activity coincide with changes on downstream 
targets, primarily GSK3β. Dysregulation of the 
ILK-signaling nexus is an important early event in 
the genesis of human colon cancer (Marotta et al., 
2003). ILK expression levels correlated with tumor 
invasion, grade and stage; higher levels in 
metastatic tumors (Bravou et al., 2003). Thymosin 
beta 4 induces colon cancer cell migration and 
clinical metastasis via enhancing 
ILK/IQGAP1/Rac1 signal transduction pathway 
(Tang et al., 2011). 
Gastric cancer 
ILK might be a novel molecular marker for 
aggressive gastric cancer. Strong expression of ILK 
is observed in the majority of primary tumors that 
were associated with tumor cell invasion and nodal 
metastasis; no expression in non-neoplastic gastric 
epithelia (Ito et al., 2003). ILK might be used as a 
potential therapeutic strategy to combat multi-drug 
resistance through blocking PI3K-Akt and MAPK-
ERK pathways in human gastric carcinoma (Song 
et al., 2012). 
Lung cancer 
ILK expression is significantly associated with 
tumor grade and stage, and lower than 5-year 
survival. Increased expression of ILK is a poor 
prognostic factor in patients with non-small cell 
lung cancer (Takanami 2005; Okamura et al., 
2007). 
Anaplastic thyroid cancer 
ILK is a potential therapeutic target for treating 
anaplastic thyroid cancer. ILK expression and 
activity are elevated in human anaplastic thyroid 
cancer and ILK inhibition leads to growth arrest 
and apoptosis in vitro and in vivo (Younes et al., 
2005). 
Squamous cell carcinoma of head 
and neck 
ILK is overexpressed in SCCHN tumor specimens. 
Targeting ILK with the small-molecule ILK 
inhibitor QLT0267 inhibits cell growth and induces 
apoptosis in SCCHN cell lines by reducing ILK 
activity and Akt phosphorylation (Younes et al., 
2007). 
Pancreatic cancer 
ILK is involved with aggressive capability in 
pancreatic cancer. Significant association between 
strong expression of ILK and poor prognosis of 
pancreatic cancer patients has been observed 
(Sawai et al., 2006). Silencing ILK could be a 
potentially useful therapeutic approach for treating 
pancreatic cancer (Schaeffer et al., 2010; Zhu et al., 
2012). 
Ovarian cancer 
ILK expression is increased with tumor 
progression; normal epithelium was negative for 
ILK (Ahmed et al., 2003). ILK gene silencing 
suppresses tumor growth in human ovarian 
carcinoma HO-8910 xenografts in mice (Li et al., 
2013) and induces apoptosis in ovarian carcinoma 
SKOV3 cell (Liu et al., 2012). 
Prostate cancer 
ILK expression is increased with tumor 
progression. Increased expression of the protein has 
been demonstrated to be inversely related to the 5-
year survival rate in prostate cancer (Graff et al., 
2001). ILK stimulates the expression of VEGF by 
stimulating HIF-1alpha protein expression in a 
PKB/Akt- and mTOR/FRAP-dependent manner 
and knockdown of ILK expression with siRNA, or 
inhibition of ILK activity, results in significant 
inhibition of HIF-1alpha and VEGF expression 
(Tan el al., 2004). Compound 22, a novel ILK 
inhibitor, exhibited high in vitro potency against a 
panel of prostate and breast cancer cell lines and its 
therapeutic potential has been suggested by its in 
vivo efficacy as a single oral agent in suppressing 
PC-3 xenograft tumor growth (Lee et al., 2011). 
Mesothelioma 
ILK is expressed in malignant mesothelioma. 
Normal mesothelial cells and lung parenchyma are 
negative (Watzka et al., 2008). Evaluating ILK's 
potential use as a marker of disease progression in 
malignant pleural mesothelioma has been suggested 
(Watzka et al., 2013). 
Ewing's sarcoma and primitive 
neuroectodermal tumor 
Expression is observed (Chung et al., 1998). 
Glioblastoma 
The ILK inhibitor, QLT0267, was able to reduce 
cellular invasion and angiogenesis of glioma cells. 
Blocking the ILK/Akt pathway is a potential 
strategy for molecular targeted therapy for gliomas 
(Kou et al., 2005; Edwards et al., 2008). Expression 
of insulin-like growth factor-binding protein 2 
(IGFBP2), a glioma oncogene emerging as a target 
for therapeutic intervention, requires ILK to induce 
cell motility and activate NF-kB (Holmes et al., 
2012). 
Musculoskeletal sarcoma 
Prognostic factor in osteosarcoma and a novel 
potential therapeutic target for the treatment of 
osteosarcoma (Rhee et al., 2013). 
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Medulloblastoma 
Expression is observed (Chung et al., 1998). 
Breast cancer, cancer cell growth 
and metastasis 
Epithelial to mesenchymal transition (EMT) causes 
fibrosis, cancer progression and metastasis. 
Acquisition of invasive and migratory 
characteristics in cancer cells results primarily from 
adopting an EMT phenotype. Overexpression of 
ILK induces EMT in mammary epithelial cells 
(Somasiri et al., 2001) and targeting this signaling 
cascade is an effective strategy for the treatment of 
fibrotic kidney (Li et al., 2009), lung (Kavvadas et 
al., 2010) or bladder cancer (Matsui et al., 2011). 
ILK is a key intracellular mediator of TGFβ-1 
induced EMT (Li et al., 2009) through a Snail and 
Slug mechanism (Serrano et al., 2013b). TGFβ-1 
mediated EMT induces an interaction between ILK 
and Rictor and disruption of this interaction by 
silencing ILK or using ILK inhibitor molecule, 
QLT0267, blocks TGFβ-1 induced EMT and 
partially reverses the mesenchymal phenotype in 
breast cancer cell lines (Serrano et al., 2013b). ILK 
promotes lung cancer cell migration and invasion 
through the induction of EMT process (Chen et al., 
2013) and is a therapeutically targetable mediator of 
ERG-induced EMT and transformation in prostate 
cancer (Becker-Santos et al., 2012) and in high 
glucose-induced epithelial-mesenchymal transition 
of renal tubular cell (Peng et al., 2012). A 
significant acceleration in mammary tumor 
incidence and growth was observed in the MMTV-
Wnt/ILK mice compared to Wnt alone, showing the 
cooperation between Wnt1 and ILK transgenes 
during mammary carcinogenesis (Oloumi et al., 
2010). Furthermore, mammary epithelial disruption 
of ILK in mice results in a profound block in 
mammary tumor induction (Pontier et al., 2010). 
ILK plays a critical role in the suppression of the 
Hippo pathway in breast, colon and prostate cancer 
cells; inactivation of ILK suppresses YAP 
activation and tumour growth in vivo (Serrano et 
al., 2013c). Expression of LIMD2 is associated with 
the metastatic process of papillary thyroid 
carcinoma (Cerutti et al., 2007) and has been 
described to bound directly to the kinase domain of 
ILK in IPP, a signal transduction pathway strongly 
linked to cell motility and invasion suggesting that 
LIMD2 potentiates ILK biological effects (Peng et 
al., 2014). 
Embryonic development 
Embryonic lethality was observed in Xenopus 
laevis (Yasunaga et al., 2005) and mouse (Sakai et 
al., 2003) models of ILK ablation, and this was 
attributed to defects in adhesive and migratory 
mechanics. 
Musculoskeletal system and skin 
Note 
During bone formation, ILK-dependent interactions 
and downstream signaling effectors are required for 
proliferation and differentiation of chondrocytes 
within the growth plate. The kinase activity of ILK 
is necessary for mechanosensing and signaling in 
vertebrate skeletal muscle (Postel et al., 2008). ILK 
is important for proliferation, adhesion, spreading 
and migration of keratinocytes (Lorenz et al., 2007; 
Nakrieko et al., 2008). ILK plays an important 
modulatory role in the normal contribution of hair 
follicle stem cell progeny to the regenerating 
epidermis following injury (Nakrieko et al., 2011). 
ILK and PI3K activation after skin wounding are 
critical for tissue repair in an HGF-dependent 
mechanism (Serrano et al., 2012). 
Disease 
Mice with depletion of ILK in chondrocytes suffer 
from dwarfism and chondrodysplasia (Grashoff et 
al., 2003; Terpstra et al., 2003). Lack of ILK in skin 
causes skin blistering and inhibition of hair follicle 
development (Lorenz et al., 2007; Nakrieko et al., 
2008). ILK deficiency in mice leads to retarded 
wound closure in skin (Serrano et al., 2012). 
Central nervous system 
Note 
The downregulation of ILK expression was found 
to inhibit axon formation through the elimination or 
length reduction of the axon. ILK-Akt-GSK3 
signaling axis is implicated in the development and 
function of neurons (Guo et al., 2007). 
Disease 
ILK deletion in the central nervous system leads to 
Cobblestone lissencephaly (Niewmierzycka et al., 
2005) and to cerebellar development and loss of 
NGF signaling (Mills et al., 2006). 
Kidney 
Note 
ILK function is required for epithelial to 
mesenchymal transition and adhesion and in the 
maintenance of glomerular filtration barrier. Human 
mesangial cells exposed to abnormal collagen I are 
protected against apoptosis by a complex 
mechanism involving integrin β1/ILK/AKT-
dependent NFkB activation with consequent Bcl-xL 
overexpression, that opposes a simultaneously 
activated ILK/GSK-3β-dependent Bim expression 
and this dual mechanism may play a role in the 
progression of glomerular dysfunction (del Nogal et 
al., 2012). ILK plays a key role in the regulation of 
renal inflammation by modulating the canonical 
NF-kB pathway, and suggest a potential therapeutic 
target for inflammatory renal diseases (Alique et al., 
2014).  
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ILK regulates expression of tubular water channel 
aquaporin-2 (AQP2) and its apical membrane 
presence in the renal tubule, polyuria and decreased 
urine osmolality were present in ILK conditional-
knockdown (cKD-ILK) adult mice compared with 
nondepleted ILK littermates pointing ILK as a 
therapeutic target in nephrogenic diabetes insipidus 
(Cano-Penalver et al., 2014). 
Disease 
Fibrosis; proteinuria (Dai et al., 2006; El-Aouni et 
al., 2006). 
Heart 
Note 
ILK plays a central role in protecting the 
mammalian heart against cardiomyopathy and 
failure. Thymosin beta4 activates ILK and 
promotes cardiac cell function and regeneration 
after infarction (Bock-Marquette et al., 2004; 
Srivastava et al., 2007). The heart uses the Integrin-
ILK-beta-parvin network to sense mechanical 
stretch (Bendig et al., 2006). Deletion of ILK 
results in disaggregation of cardiomyocytes, 
associated with disruption of adhesion signaling 
through the beta1-integrin/FAK (focal adhesion 
kinase) complex (White et al., 2006). ILK is 
implicated in cardiac hypertrophy and contractility 
and is a novel cardiotropic factor that promotes 
recruitment of human fetal heart cells to a 
cardiomyogenic fate (Traister et al., 2012). 
Increased expression of integrin-linked kinase 
improves cardiac function and decreases mortality 
in dilated cardiomyopathy model of rats (Gu et al., 
2012). In Drosophila, severely compromised 
integrin/ILK pathway function is detrimental for the 
heart, but fine-tuned moderate reduction maintains 
youthful cardiac performance, suggesting a dual 
role for this complex in regulating cardiac integrity 
and aging (Nishimura et al., 2014). 
Disease 
Cardiomyogenesis 
Blood vessels 
Note 
ILK closely regulates capillary formation and the 
survival of progenitor and differentiated endothelial 
cells. In endothelial cells, VEGF stimulates ILK 
activity, and inhibition of ILK expression or 
activity results in the inhibition of VEGF-mediated 
endothelial cell migration, capillary formation in 
vitro, and angiogenesis in vivo (Tan et al., 2004). 
ILK controls postnatal vasculogenesis by 
recruitment of endothelial progenitor cells to 
ischemic tissue (Lee et al., 2006). ILK acts as a 
regulatory partner of eNOS in vivo that prevents 
eNOS uncoupling, and suggest ILK as a therapeutic 
target for prevention of endothelial dysfunction 
related to shear stress-induced vascular diseases 
(Herranz et al., 2012). ILK regulates retinal 
vascular endothelial proliferation, migration and 
tube formation and targeting ILK may be a 
potentially useful therapeutic approach for treating 
ocular neovascularization (Xie et al., 2013). 
Deletion of ILK in mice leads to increased vascular 
content and increased activity of sGC (soluble 
Guanylyl Cyclase) and PKG (Protein Kinase G), 
resulting in a more intense vasodilatory response to 
nitric oxide donors (Serrano et al., 2013a). 
Disease 
Tumor angiogenesis (Tan et al., 2004). 
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